Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE- COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022

• Authors: ANGELA MC Rose; NICOLAY Nathalie; MARTIN Virginia Sandonis; MAZAGATOS Clara; PETROVIC Goranka; BARUCH Joaquin; DENAYER Sarah; SEYLER Lucie; DOMEGAN Lisa; LAUNAY Odile; MACHADO Ausenda; BURGUI Cristina; VAIKUTYTE Roberta; NIESSEN F Annabel; LOGHIN Isabela I; HUSA Petr; AOUALI Nassera; PANAGIOTAKOPOULOS George; TOLKSDORF Kristin; HORVATH Judit Krisztina; HOWARD Jennifer; POZO Francisco; GALLARDO Virtudes; NONKOVIC Diana; DZIUGYTE Ausra; BOSSUYT Nathalie; DEMUYSER Thomas; DUFFY Roisin; NGUYEN Liem binh Luong; KISLAYA Irina; MARTINEZ-BAZ Ivan; GEFENAITE Giedre; KNOL Mirjam J; POPESCU Corneliu; SOUČKOVÁ Lenka; SIMON Marc; MICHELAKI Stella; REICHE Janine; FERENCZI Annamaria; DELGADO-SANZ Concepcion; MAKARIC Zvjezdana Lovric; CAUCHI John Paul; BARBEZANGE Cyril; ELS Van Nedervelde; DONNELL Joan; DURIER Christine; GUIOMAR Raquel; CASTILLA Jesus; JONIKAITE Indre; BRUIJNING-VERHAGEN Patricia C J L; LAZAR Mihaela; DEMLOVÁ Regina; WIRTZ Gil; AMERALI Marina; DUERRWALD Ralf; KUNSTAR Mihaly Pal; KISSLING Esther; BACCI Sabrina; VALENCIANO Marta; KARABUVA Svjetlana; MLADINOV Suzana; MARKIC Johko; PETRIC Petra Tomah; TABAIN Irena; ILIC Maja; MLINARIC Ivan; SMOLJO Petra; NOVOSEL Iva Pem; MELILLO Tanya; BORG Maria-Louise; LISSOIR Benedicte; HOLEMANS Xavier; HAINAUT Marc; DAUBY Nicolas; DELAERE Benedicte; BOURGEOIS Marc; PETIT Evelyn; REYNDERS Marijke; JOUCK Door; MAGERMAN Koen; BLEYEN Marieke; VERMEULEN Melissa; FIERENS Sebastien; DUFRASNE Francois; DAELEMANS Siel; KERWI Ala'a Al; BERTHET Francoise; FAGHERAZZI Guy; ALEXANDRE Myriam; BENNETT Charlene; CHRISTLE Jim; CONNELL Jeff; DORAN Peter; FEENEY Laura; MAHARJAN Binita; MCDERMOTT Sinead; MCNAMARA Rosa; NURDIN Nadra; LESIEUR Zineb; CISSE Salif Mamadou; HONNEUR Anne-Sophie; DUVAL Xavier; COSTA Yolande; NADHIRA Fidouh; GALTIER Florence; CRANTELLE Laura; FOULONGNE Vincent; VANHEMS Phillipe; AMOUR Selilah; LINA Bruno; LAINE Fabrice; GALLAIS Laetitia; LAGATHU Gisele; MAISA Anna; BERNARD-STOECKLIN Sibylle; SAIDI Yacine; BAUER Rebecca; RODRIGUES Ana Paula; SILVA Adriana; GOMEZ Veronica; TAVARES Margarida; PEREIRA Debora; MANATA Maria Jose; GRUNER Heidi; ALMEIDA Andre; PINTO Paula; BARBARA Cristina; MIQUELEIZ Ana; NAVASCUES Ana; TROBAJO-SANMARTIN Camino; EZPELETA Carmen; EGUEES Nerea; CENOZ Manuel Garcia; ARDANAZ Eva; GUEVARA Marcela; MORENO-IRIBAS Conchi; CASADO Itziar; MICKIENE Aukse; KULIESE Monika; ORLIKOVA Hana; DOROBAT Carmen Mihaela; MANCIUC Carmen; FLORESCU Simin Aysel; MARIN Alexandru; DINU Sorin; PASCU Catalina; IVANCIUC Alina; BISTRICEANU Iulia; OPREA Mihaela; MIHAI Maria Elena; BUDA Silke; PREUSS Ute; WEDDE Marianne; OROSZI Beatrix; KRISZTALOVICS Katalin; TURI Gergo; KRISTOF Katalin; VARGA Csaba; LI Ruoran; MOREN Alain; NARDONE Anthony
• Year of publication: 2023
• Type: Article in Periodical
• Magazine / Source: EUROSURVEILLANCE
• MU Faculty or unit: Faculty of Medicine
• Web: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2023.28.47.2300187
• Doi: http://dx.doi.org/10.2807/1560-7917.ES.2023.28.47.2300187
• Keywords: COVID-19; Europe; hospital; omicron; SARS-CoV-2; vaccine effectiveness
• Description: Introduction: The I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients >= 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period). Methods: In both networks, 46 hospitals (13 countries) follow a similar test-negative case-control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received >= 14 days before symptom onset (stratifying first booster into received < 150 and >= 150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition. Results: We included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29-54) for complete PSV (with last dose received >= 150 days before onset), while it was 59% (95% CI: 51-66) after addition of one booster dose. The VE was 85% (95% CI: 78-89), 70% (95% CI: 61-77) and 36% (95% CI: 17-51) for those with onset 14-59 days, 60-119 days and 120-179 days after booster vaccination, respectively. Conclusions: Our results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset < 120 days after first booster dose.